CA2205091A1 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
CA2205091A1
CA2205091A1 CA002205091A CA2205091A CA2205091A1 CA 2205091 A1 CA2205091 A1 CA 2205091A1 CA 002205091 A CA002205091 A CA 002205091A CA 2205091 A CA2205091 A CA 2205091A CA 2205091 A1 CA2205091 A1 CA 2205091A1
Authority
CA
Canada
Prior art keywords
enzyme
dna
prodrug
cells
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002205091A
Other languages
English (en)
French (fr)
Inventor
Christopher John Taylorson
Hendrikus Johannes Eggelte
Antonio Tarragona-Fiol
Brian Robert Rabin
Francis Thomas Boyle
John Frederick Hennam
David Charles Blakey
Peter Robert Marsham
David William Heaton
David Huw Davies
Anthony Michael Slater
Laurent Francois Andre Hennequin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London Biotechnology Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2205091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by Individual filed Critical Individual
Publication of CA2205091A1 publication Critical patent/CA2205091A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CA002205091A 1994-12-23 1995-12-21 Chemical compounds Abandoned CA2205091A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9426192.2 1994-12-23
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
GB9516810.0 1995-08-16

Publications (1)

Publication Number Publication Date
CA2205091A1 true CA2205091A1 (en) 1996-07-04

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205091A Abandoned CA2205091A1 (en) 1994-12-23 1995-12-21 Chemical compounds

Country Status (23)

Country Link
US (1) US5985281A (enExample)
EP (1) EP0806964B1 (enExample)
JP (1) JP3805365B2 (enExample)
KR (1) KR100270650B1 (enExample)
CN (1) CN1095677C (enExample)
AT (1) ATE222124T1 (enExample)
AU (1) AU701916B2 (enExample)
BR (1) BR9510490B1 (enExample)
CA (1) CA2205091A1 (enExample)
CZ (1) CZ195297A3 (enExample)
DE (1) DE69527805T2 (enExample)
ES (1) ES2181805T3 (enExample)
FI (1) FI972683L (enExample)
HU (1) HUT77450A (enExample)
IL (1) IL116511A0 (enExample)
MX (1) MX9704575A (enExample)
NO (1) NO972882L (enExample)
NZ (1) NZ297529A (enExample)
PL (1) PL184031B1 (enExample)
RU (1) RU2189251C2 (enExample)
SK (1) SK80997A3 (enExample)
TR (1) TR199501654A2 (enExample)
WO (1) WO1996020011A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9610050A (pt) * 1995-08-16 1999-10-13 Zeneca Ltd Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo
TW406454B (en) 1996-10-10 2000-09-21 Berg Tech Inc High density connector and method of manufacture
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
ATE499115T1 (de) * 1998-09-18 2011-03-15 Immunomedics Inc Antikörper verwiesene enzymprodrugtherapie mit glukuronidase
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
KR20020073127A (ko) * 1999-09-17 2002-09-19 겐자임 트랜스제닉스 코포레이션 형질전환에 의하여 생성된 융합 단백질
WO2002064093A2 (en) 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
BR0316643A (pt) * 2002-11-27 2005-10-11 Gtc Biotherapeutics Inc Anticorpos modificados estavelmente produzidos no leite e método de produzir os mesmos
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
EP1945666B1 (en) * 2005-10-21 2013-03-27 GTC Biotherapeutics, Inc. Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
WO2007149827A2 (en) * 2006-06-20 2007-12-27 Janssen Pharmaceutica, N.V. Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
CN101511774B (zh) * 2006-10-03 2015-05-13 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的芥子气类化合物及其相关化合物的前药
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
EP2279003A4 (en) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF INFLAMMATORY DISEASES
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
ES2075893T3 (es) * 1989-01-23 1995-10-16 Akzo Nobel Nv Activacion in vivo especifica de sede de farmacos terapeuticos.
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
EP0625205A1 (en) * 1992-01-30 1994-11-23 Genzyme Limited Chiral synthesis with modified enzymes
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
NO972882L (no) 1997-08-19
TR199501654A2 (tr) 1996-07-21
NZ297529A (en) 1999-07-29
FI972683A0 (fi) 1997-06-19
FI972683A7 (fi) 1997-06-19
BR9510490B1 (pt) 2010-10-05
MX9704575A (es) 1997-10-31
NO972882D0 (no) 1997-06-20
DE69527805T2 (de) 2003-04-24
TR199501654A3 (enExample) 1996-07-21
WO1996020011A1 (en) 1996-07-04
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
ATE222124T1 (de) 2002-08-15
CZ195297A3 (en) 1997-12-17
RU2189251C2 (ru) 2002-09-20
DE69527805D1 (de) 2002-09-19
HUT77450A (hu) 1998-04-28
FI972683L (fi) 1997-06-19
JPH10511547A (ja) 1998-11-10
US5985281A (en) 1999-11-16
CN1095677C (zh) 2002-12-11
JP3805365B2 (ja) 2006-08-02
AU701916B2 (en) 1999-02-11
ES2181805T3 (es) 2003-03-01
CN1171054A (zh) 1998-01-21
EP0806964A1 (en) 1997-11-19
IL116511A0 (en) 1996-07-23
PL184031B1 (pl) 2002-08-30
BR9510490A (pt) 1998-01-13
EP0806964B1 (en) 2002-08-14
AU4269796A (en) 1996-07-19
SK80997A3 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
CA2205091A1 (en) Chemical compounds
AU719513B2 (en) Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
EP0979292B1 (en) Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
AU720223B2 (en) Serpin enzyme complex receptor-mediated gene transfer
US8993295B2 (en) Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US6436691B1 (en) Chemical compounds
JP2000504218A (ja) リガンド指令酵素プロドラッグ療法
JP5330826B2 (ja) Ｔａｂ分子

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued